- Higher Sustained Virologic Response (SVR-12) Achievable in Liver Transplant (LT) Recipients with Hepatitis C (HCV) Treated with Protease Inhibitor (PI) Triple Therapy (TT)Stravitz R Todd; Levitsky Josh; Dodge Jennifer L; Saxena Varun; Burton James R; Verna Elizabeth C; O'Leary Jacqueline G; Parikh Neehar D; Everson Gregory T; Brown Robert S; Trotter James; Terrault Norah64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013-11-01 To 2013-11-05.被引 3
- Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life SettingsDario, Cattaneo; Salvatore, Sollima; Paola, Meraviglia; Laura, Milazzo; Davide, Minisci; Marta, Fusi; Carlo, Filice; Cristina, GervasoniDRUGS IN R&D, 2020, 20(2): 155-160.
- Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levelsDeng, Rui; Fan, Rong; Sun, Jian*Journal of Hepatology, 2022, 77(4): 1223-1224.被引 1
会议论文
Protease-Inhibitor (PI) Triple Therapy (TT) in Mildly Decompensated Cirrhotics: Predictors of Treatment Discontinuation, Worsening Decompensation and Sustained Virologic Response
15阅读
